Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
CRBP Stock Overview
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases.
Corbus Pharmaceuticals Holdings Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.22 |
52 Week High | US$1.32 |
52 Week Low | US$0.21 |
Beta | 1.93 |
1 Month Change | -21.45% |
3 Month Change | -35.04% |
1 Year Change | -80.40% |
3 Year Change | -96.05% |
5 Year Change | -96.64% |
Change since IPO | -92.62% |
Recent News & Updates
Corbus Pharmaceuticals GAAP EPS of -$0.11
Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q2 GAAP EPS of -$0.11. As of June 30, 2022, the Company has $74 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures.
Shareholder Returns
CRBP | US Biotechs | US Market | |
---|---|---|---|
7D | -16.2% | -2.0% | 1.1% |
1Y | -80.4% | -23.0% | -9.0% |
Return vs Industry: CRBP underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: CRBP underperformed the US Market which returned -9% over the past year.
Price Volatility
CRBP volatility | |
---|---|
CRBP Average Weekly Movement | 12.7% |
Biotechs Industry Average Movement | 12.3% |
Market Average Movement | 7.6% |
10% most volatile stocks in US Market | 17.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRBP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: CRBP's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 41 | Yuval Cohen | https://www.corbuspharma.com |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation.
Corbus Pharmaceuticals Holdings Fundamentals Summary
CRBP fundamental statistics | |
---|---|
Market Cap | US$27.75m |
Earnings (TTM) | -US$35.12m |
Revenue (TTM) | US$97.32k |
287.7x
P/S Ratio-0.8x
P/E RatioIs CRBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRBP income statement (TTM) | |
---|---|
Revenue | US$97.32k |
Cost of Revenue | US$20.25m |
Gross Profit | -US$20.15m |
Other Expenses | US$14.98m |
Earnings | -US$35.12m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.28 |
Gross Margin | -20,701.99% |
Net Profit Margin | -36,089.12% |
Debt/Equity Ratio | 38.8% |
How did CRBP perform over the long term?
See historical performance and comparisonValuation
Is CRBP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRBP?
Other financial metrics that can be useful for relative valuation.
What is CRBP's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$27.75m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does CRBP's PB Ratio compare to its peers?
CRBP PB Ratio vs Peers |
---|
Company | PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.8x | ||
ENZN Enzon Pharmaceuticals | 7.6x | n/a | US$25.1m |
AIKI AIkido Pharma | 0.4x | -10.6% | US$32.4m |
AGTC Applied Genetic Technologies | 0.6x | 6.0% | US$28.5m |
AURX Nuo Therapeutics | 14.4x | n/a | US$51.4m |
CRBP Corbus Pharmaceuticals Holdings | 0.6x | 9.4% | US$27.7m |
Price-To-Book vs Peers: CRBP is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (5.8x).
Price to Earnings Ratio vs Industry
How does CRBP's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: CRBP is good value based on its Price-To-Book Ratio (0.6x) compared to the US Biotechs industry average (1.9x)
Price to Book Ratio vs Fair Ratio
What is CRBP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 0.6x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate CRBP's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CRBP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CRBP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CRBP's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Future Growth
How is Corbus Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
9.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRBP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRBP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRBP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRBP's revenue (79.1% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: CRBP's revenue (79.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRBP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Corbus Pharmaceuticals Holdings performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-10.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRBP is currently unprofitable.
Growing Profit Margin: CRBP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CRBP is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.
Accelerating Growth: Unable to compare CRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: CRBP has a negative Return on Equity (-71%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Corbus Pharmaceuticals Holdings's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CRBP's short term assets ($75.2M) exceed its short term liabilities ($15.6M).
Long Term Liabilities: CRBP's short term assets ($75.2M) exceed its long term liabilities ($17.0M).
Debt to Equity History and Analysis
Debt Level: CRBP has more cash than its total debt.
Reducing Debt: CRBP's debt to equity ratio has increased from 0.1% to 38.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRBP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CRBP has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 25% each year.
Discover healthy companies
Dividend
What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRBP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRBP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRBP has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Yuval Cohen (47 yo)
8.33yrs
Tenure
US$4,843,519
Compensation
Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc...
CEO Compensation Analysis
Compensation vs Market: Yuval's total compensation ($USD4.84M) is above average for companies of similar size in the US market ($USD758.99K).
Compensation vs Earnings: Yuval's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: CRBP's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
Experienced Board: CRBP's board of directors are considered experienced (5.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CRBP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Corbus Pharmaceuticals Holdings, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Corbus Pharmaceuticals Holdings, Inc.
- Ticker: CRBP
- Exchange: NasdaqCM
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$27.747m
- Shares outstanding: 125.27m
- Website: https://www.corbuspharma.com
Number of Employees
Location
- Corbus Pharmaceuticals Holdings, Inc.
- 500 River Ridge Drive
- Norwood
- Massachusetts
- 2062
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/08/18 00:00 |
End of Day Share Price | 2022/08/18 00:00 |
Earnings | 2022/06/30 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.